Stock picks with research | support | resistance and technical analysis for trading | Day trading | stock investing in the market

• About US

Market Activity

Premium Plan

Trading Technologies

Day Trading

Stock Trading

Stock Trading Strategy

Technical Strategy

Breakout Stocks

Penny Stock investing

stock Breakout for day trading

Stock : EBS	\| Stock Recommendations : Buy
Sector : Biotech & Drugs	\| First resistance : 18.19
Stock Name : EMERGENT BIOSOLUTIONS INC COM	\| Second resistance :
Buy Near :	\| Third resistance :
StopLoss :	\| First Support : 16.11
Posted date : 11/2/2008 12:00:00 AM	\| Second Support : 14.60

Emergent BioSolutions Inc. com (EBS) Stock has given a buy signal, with rising moving average. Stockhastic and ADX also given a buy signal.

Emergent BioSolutions Inc. com (EBS) announced on 10/1/08, it will receive between $364 million and $404 million for new contracts to supply the U.S. government with anthrax vaccines. Emergent BioSolutions Inc. com (EBS) is a Biotechnology company. As per technical analysis, Stock analysis and fundamentally this Stock looks good candidate for portfolio investment. Emergent BioSolutions Inc. com Stock you can consider for Stock Market Investment, Swing Trading, Stock trading, Stock Investing, Day trading, Stock picks, Breakout Stocks. Due to Stock market and economic condition keep tight stop loss on all position. You can buy this Stock near $18

Portfolio stock

Recent News Head Lines

FOCUS-Wanted: More high-tech manufacturing space for a global vaccine push
(Thu, 25 Feb 2021 12:00:00 +0000)
The number of available COVID-19 vaccine doses is steadily rising, but a shortage of physical space that meets standards for pharmaceutical manufacturing is a major bottleneck to further expansion, according to drugmakers, industry construction experts and officials involved in the U.S. vaccine program. The production of raw materials, vaccine formulation and vial filling all require "clean rooms" with features like air cleaners, sterile water and sterilizing steam designed and in some cases built by specialists. Moderna Inc on Wednesday announced plans to expand vaccine manufacturing capacity, but said it will be a year before that can add to its production.

Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021
(Wed, 24 Feb 2021 15:07:15 +0000)
Upgrades For Emergent BioSolutions Inc (NYSE:EBS), Chardan Capital upgraded the previous rating of Neutral to Buy. Emergent BioSolutions earned $3.67 in the fourth quarter, compared to $1.57 in the year-ago quarter. At the moment, the stock has a 52-week-high of $137.61 and a 52-week-low of $46.37. Emergent BioSolutions closed at $93.65 at the end of the last trading period. According to Raymond James, the prior rating for Xencor Inc (NASDAQ:XNCR) was changed from Market Perform to Outperform. In the fourth quarter, Xencor showed an EPS of $0.24, compared to $0.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $55.33 and a 52-week-low of $19.35. Xencor closed at $48.35 at the end of the last trading period. For Bank of Montreal (NYSE:BMO), Credit Suisse upgraded the previous rating of Neutral to Outperform. Bank of Montreal earned $2.35 in the first quarter, compared to $1.86 in the year-ago quarter. The current stock performance of Bank of Montreal shows a 52-week-high of $83.79 and a 52-week-low of $38.31. Moreover, at the end of the last trading period, the closing price was at $83.44. Deutsche Bank upgraded the previous rating for McAfee Corp (NASDAQ:MCFE) from Hold to Buy. McAfee earned $0.38 in the fourth quarter. At the moment, the stock has a 52-week-high of $22.14 and a 52-week-low of $14.80. McAfee closed at $19.45 at the end of the last trading period. According to HSBC, the prior rating for Greencore Group PLC (OTC:GNCGY) was changed from Hold to Buy. The stock has a 52-week-high of $8.35 and a 52-week-low of $4.71. At the end of the last trading period, Greencore Group closed at $7.59. For Tomra Systems ASA (OTC:TMRAY), Kepler Cheuvreux upgraded the previous rating of Hold to Buy. The stock has a 52-week-high of $49.05 and a 52-week-low of $20.84. At the end of the last trading period, Tomra Systems closed at $44.27. According to Barclays, the prior rating for BNP Paribas (OTC:BNPQY) was changed from Underweight to Equal-Weight. At the moment, the stock has a 52-week-high of $27.85 and a 52-week-low of $13.18. BNP Paribas closed at $30.15 at the end of the last trading period. JP Morgan upgraded the previous rating for Credit Agricole SA (OTC:CRARY) from Neutral to Overweight. The stock has a 52-week-high of $6.64 and a 52-week-low of $3.15. At the end of the last trading period, Credit Agricole closed at $6.85. According to JP Morgan, the prior rating for Enagas SA (OTC:ENGGY) was changed from Underweight to Neutral. The current stock performance of Enagas shows a 52-week-high of $13.20 and a 52-week-low of $9.41. Moreover, at the end of the last trading period, the closing price was at $10.60. According to KeyBanc, the prior rating for BigCommerce Holdings Inc (NASDAQ:BIGC) was changed from Sector Weight to Overweight. In the fourth quarter, BigCommerce Holdings earned $0.12. The stock has a 52-week-high of $162.50 and a 52-week-low of $53.19. At the end of the last trading period, BigCommerce Holdings closed at $63.33. See all analyst ratings upgrades. Downgrades For Cooper Tire & Rubber Co (NYSE:CTB), Standpoint Research downgraded the previous rating of Buy to Sell. For the fourth quarter, Cooper Tire & Rubber had an EPS of $0.75, compared to year-ago quarter EPS of $1.02. At the moment, the stock has a 52-week-high of $58.19 and a 52-week-low of $13.82. Cooper Tire & Rubber closed at $57.92 at the end of the last trading period. According to Berenberg, the prior rating for Kosmos Energy Ltd (NYSE:KOS) was changed from Buy to Hold. In the fourth quarter, Kosmos Energy showed an EPS of $0.12, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $5.23 and a 52-week-low of $0.50. At the end of the last trading period, Kosmos Energy closed at $2.99. According to Piper Sandler, the prior rating for Webster Financial Corp (NYSE:WBS) was changed from Overweight to Neutral. Webster Financial earned $0.99 in the fourth quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Webster Financial shows a 52-week-high of $55.41 and a 52-week-low of $18.16. Moreover, at the end of the last trading period, the closing price was at $55.24. For United Utilities Group PLC (OTC:UUGRY), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. At the moment, the stock has a 52-week-high of $26.30 and a 52-week-low of $17.28. United Utilities Group closed at $25.95 at the end of the last trading period. For Natixis SA (OTC:NTXFF), Barclays downgraded the previous rating of Overweight to Equal-Weight. The current stock performance of Natixis shows a 52-week-high of $4.15 and a 52-week-low of $2.05. Moreover, at the end of the last trading period, the closing price was at $4.60. Deutsche Bank downgraded the previous rating for InterContinental Hotels Group PLC (NYSE:IHG) from Buy to Hold. In the second quarter, InterContinental Hotels earned $0.89. The stock has a 52-week-high of $75.20 and a 52-week-low of $25.39. At the end of the last trading period, InterContinental Hotels closed at $73.94. For Systemax Inc (NYSE:SYX), William Blair downgraded the previous rating of Outperform to Market Perform. In the fourth quarter, Systemax showed an EPS of $0.42, compared to $0.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of $45.35 and a 52-week-low of $14.00. Systemax closed at $44.58 at the end of the last trading period. See all analyst ratings downgrades. Initiations Morgan Stanley initiated coverage on Synaptics Inc (NASDAQ:SYNA) with an Overweight rating. The price target for Synaptics is set to $173.00. In the second quarter, Synaptics showed an EPS of $2.30, compared to $2.04 from the year-ago quarter. The stock has a 52-week-high of $137.28 and a 52-week-low of $44.41. At the end of the last trading period, Synaptics closed at $130.12. Small Cap Consumer Research initiated coverage on Boomer Holdings Inc (OTC:BOMH) with a Buy rating. The price target for Boomer Holdings is set to $1.50. The stock has a 52-week-high of $5.01 and a 52-week-low of $0.34. At the end of the last trading period, Boomer Holdings closed at $0.60. For NEL ASA (OTC:NLLSF), JP Morgan initiated coverage, by setting the current rating at Neutral. The stock has a 52-week-high of $3.30 and a 52-week-low of $0.78. At the end of the last trading period, NEL closed at $3.04. JP Morgan initiated coverage on ITM Power PLC (OTC:ITMPF) with an Overweight rating. The stock has a 52-week-high of $7.25 and a 52-week-low of $1.13. At the end of the last trading period, ITM Power closed at $7.15. For Gamesys Group PLC (OTC:JKPTF), Jefferies initiated coverage, by setting the current rating at Buy. The current stock performance of Gamesys Group shows a 52-week-high of $17.07 and a 52-week-low of $9.47. Moreover, at the end of the last trading period, the closing price was at $18.95. With an Outperform rating, SVB Leerink initiated coverage on LENSAR Inc (NASDAQ:LNSR). The price target seems to have been set at $20.00 for LENSAR. In the third quarter, LENSAR showed an EPS of $0.64, compared to $5.44 from the year-ago quarter. The stock has a 52-week-high of $12.71 and a 52-week-low of $3.16. At the end of the last trading period, LENSAR closed at $9.50. Jefferies initiated coverage on 888 Holdings PLC (OTC:EIHDF) with a Buy rating. The current stock performance of 888 Holdings shows a 52-week-high of $4.09 and a 52-week-low of $1.04. Moreover, at the end of the last trading period, the closing price was at $4.08. With an Outperform rating, William Blair initiated coverage on Taysha Gene Therapies Inc (NASDAQ:TSHA). The price target seems to have been set at $46.00 for Taysha Gene Therapies. Interestingly, in the third quarter, Taysha Gene Therapies's EPS was $1.28. The current stock performance of Taysha Gene Therapies shows a 52-week-high of $33.35 and a 52-week-low of $18.16. Moreover, at the end of the last trading period, the closing price was at $26.66. With an Outperform rating, William Blair initiated coverage on Generation Bio Co (NASDAQ:GBIO). The price target seems to have been set at $45.00 for Generation Bio. In the third quarter, Generation Bio showed an EPS of $0.46, compared to $3.31 from the year-ago quarter. The current stock performance of Generation Bio shows a 52-week-high of $55.72 and a 52-week-low of $18.80. Moreover, at the end of the last trading period, the closing price was at $34.48. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Preview: Edison IntlA Preview Of EOG Resources's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Why Emergent BioSolutions Stock Is Sliding Today
(Fri, 19 Feb 2021 16:27:00 +0000)
Shares of Emergent BioSolutions (NYSE: EBS) were sliding 9.3% lower as of 11:13 a.m. EST on Friday. The decline came after Chardan Capital analyst Keay Nakae downgraded the stock from buy to hold. Nakae set a one-year price target for Emergent Biosolutions of $112, more than 4% below the stock's closing price on Thursday.

Looking Into Emergent BioSolutions's Return On Capital Employed
(Fri, 19 Feb 2021 15:57:44 +0000)
Looking at Q4, Emergent BioSolutions (NYSE:EBS) earned $258.10 million, a 321.04% increase from the preceding quarter. Emergent BioSolutions also posted a total of $583.00 million in sales, a 51.35% increase since Q3. Emergent BioSolutions earned $61.30 million, and sales totaled $385.20 million in Q3. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Emergent BioSolutions posted an ROCE of 0.18%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on EBS Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. In Emergent BioSolutions's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions. Q4 Earnings Recap Emergent BioSolutions reported Q4 earnings per share at $3.67/share, which beat analyst predictions of $3.19/share. See more from BenzingaClick here for options trades from BenzingaBenzinga's Top Ratings Upgrades, Downgrades For February 19, 2021Emergent BioSolutions: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Emergent BioSolutions Inc (EBS) Q4 2020 Earnings Call Transcript
(Fri, 19 Feb 2021 09:01:07 +0000)
EBS earnings call for the period ending December 31, 2020.

Never go against major trend for day trading | stock trading

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

All Rights Reserved © 2000-2006 Flyingstock.com
Chart courtesy of StockCharts.com
Portfolio stock - EMERGENT BIOSOLUTIONS INC COM for Stock investing stock trading day trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.